{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16"],"submitter":["Jing F"],"pubmed_abstract":["<h4>Background</h4>Effective therapies for pulmonary fibrosis caused by coronavirus disease (COVID-19) and other etiologies are lacking. Our previous studies demonstrated that Fuzheng Huayu tablet (FZHY), a traditional Chinese medicine known for its anti-liver fibrotic properties, can improve lung function in patients with chronic obstructive pulmonary disease and attenuate bleomycin-induced pulmonary fibrosis in rats.<h4>Purpose</h4>This study aimed to evaluate the efficacy and safety of FZHY in post-COVID-19 pulmonary fibrosis.<h4>Methods</h4>A multi-center, randomized, double-blind, placebo-controlled clinical trial was conducted to evaluate the efficacy of a 24-week treatment with FZHY, combined with vitamin C and respiratory function rehabilitation, for treating pulmonary fibrosis in "],"journal":["Frontiers in pharmacology"],"pagination":["1508276"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11933019"],"repository":["biostudies-literature"],"pubmed_title":["Fuzheng Huayu tablets for treating pulmonary fibrosis in post-COVID-19 patients: a multicenter, randomized, double-blind, placebo-controlled trial."],"pmcid":["PMC11933019"],"pubmed_authors":["Peng Y","Huang J","Ke J","Qiu Q","Zhao Z","Wu H","Zhang W","Huang T","Feng J","Zhan S","Xing F","Jiang B","Wang W","Liu C","Su W","Jing F"],"additional_accession":[]},"is_claimable":false,"name":"Fuzheng Huayu tablets for treating pulmonary fibrosis in post-COVID-19 patients: a multicenter, randomized, double-blind, placebo-controlled trial.","description":"<h4>Background</h4>Effective therapies for pulmonary fibrosis caused by coronavirus disease (COVID-19) and other etiologies are lacking. Our previous studies demonstrated that Fuzheng Huayu tablet (FZHY), a traditional Chinese medicine known for its anti-liver fibrotic properties, can improve lung function in patients with chronic obstructive pulmonary disease and attenuate bleomycin-induced pulmonary fibrosis in rats.<h4>Purpose</h4>This study aimed to evaluate the efficacy and safety of FZHY in post-COVID-19 pulmonary fibrosis.<h4>Methods</h4>A multi-center, randomized, double-blind, placebo-controlled clinical trial was conducted to evaluate the efficacy of a 24-week treatment with FZHY, combined with vitamin C and respiratory function rehabilitation, for treating pulmonary fibrosis in ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-04-08T19:46:58.357Z","creation":"2025-07-04T03:05:47.81Z"},"accession":"S-EPMC11933019","cross_references":{"pubmed":["40135237"],"doi":["10.3389/fphar.2025.1508276"]}}